Join
Live feed
·
NEWSReleasevia Quantisnow
Jaguar Health Inc. logo

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

ByQuantisnow·Wall Street's wire, on your screen.
JAGX· Jaguar Health Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JAGX (Jaguar Health Inc.) and more on Quantisnow.